Assessment of “Ca2+-antagonist” effects of drugs in K+-depolarized smooth muscle

M. Spedding

DOI: https://doi.org/10.1007/BF00500485

1982-02-01

Abstract:

What problem does this paper attempt to address?

Buprenorphine for Chronic Pain Treatment and Elective Orthopaedic Surgery: a US National Database Analysis

Alexander B. Stone,Haoyan Zhong,Jashvant Poeran,Jiabin Liu,Crispiana Cozowicz,Alex Illescas,Stavros G. Memtsoudis

DOI: https://doi.org/10.1016/j.bja.2022.11.013

IF: 11.719

2023-01-01

British Journal of Anaesthesia

Abstract:Editor—Buprenorphine is a partial μ-opioid receptor agonist that is increasingly used for treatment of chronic pain.1,2 Buprenorphine has been reported to be associated with less respiratory depression and fewer adverse effects compared with full μ-opioid receptor agonists.2,3 Acute pain management of patients taking buprenorphine perioperatively can pose a challenge, and there is debate as to whether to continue buprenorphine in the perioperative period.4 The American Society of Regional Anesthesia and Pain Medicine recommends that patients prescribed buprenorphine for opioid use disorder be maintained on treatment during the perioperative period if possible, and be returned to their preoperative dose as soon as possible if treatment is interrupted.
Effects of Remifentanil Gradual Withdrawal Combined with Postoperative Infusion on Postoperative Hyperalgesia in Patients Undergoing Laparoscopic hysterectomy: A Factorial Design, Double-Blind, Randomized Controlled Trial

Meng Luo,Xue Han,Huan Li,Guangyue Zhou,Haoxuan Chen,Fang Gao

DOI: https://doi.org/10.2147/dddt.s451913

IF: 4.3188

2024-02-28

Drug Design Development and Therapy

Abstract:Meng Luo, 1, 2, &ast Xue Han, 1, 2, &ast Huan Li, 1, 2 Guangyue Zhou, 1, 2 Haoxuan Chen, 1, 2 Fang Gao 1, 2 1 Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China; 2 Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fang Gao, Department of Anesthesiology, the Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Xuzhou, Jiangsu, 221002, People's Republic of China, Tel +86-18052268331, Email Background: Remifentanil-induced hyperalgesia (RIH) increases the risk of persistent postoperative pain, making early postoperative analgesic therapy ineffective and affecting postoperative patient satisfaction. This study aimed to verify the effects of gradual withdrawal of remifentanil combined with postoperative pump infusion of remifentanil on postoperative hyperalgesia and pain in patients undergoing laparoscopic hysterectomy. Methods: This trial was a factorial design, double-blind, randomized controlled trial. Patients undergoing laparoscopic hysterectomy were randomly allocated to the control group, postoperative pump infusion of remifentanil group, gradual withdrawal of remifentanil group, or gradual withdrawal plus postoperative pump infusion of remifentanil group (n = 35 each). The primary outcome was postoperative mechanical pain thresholds in the medial forearm. The secondary outcomes included postoperative mechanical pain thresholds around the incision, pain numeric rating scale scores, analgesic utilization, awakening agitation or sedation scores, a 15-item quality of recovery survey, and postoperative complications. Results: Gradual withdrawal of remifentanil significantly increased postoperative pain thresholds versus abrupt discontinuation ( P < 0.05), whereas postoperative infusion did not show significant differences compared to the absence of infusion ( P > 0.05). The combined gradual withdrawal and postoperative infusion group exhibited the highest thresholds and had the lowest postoperative pain scores and analgesic requirements as well as the highest quality of recovery scores ( P < 0.05). No significant differences were observed for agitation scores, sedation scores, or complication rates ( P > 0.05). Conclusion: The novel combined gradual withdrawal and postoperative infusion of remifentanil uniquely attenuates postoperative hyperalgesia, pain severity, analgesic necessity, and improves recovery quality after laparoscopic hysterectomy. Keywords: opioid-induced hyperalgesia, remifentanil-induced hyperalgesia, laparoscopic hysterectomy, mechanical pain thresholds, postoperative recovery Opioid-induced hyperalgesia (OIH) represents a paradoxical reduction in pain thresholds following opioid administration, manifesting primarily as hypersensitivity to painful stimuli. 1 Proposed OIH mechanisms include increased activation of downstream pain pathways by opioids, 2 the induction of long-term potentiation (LTP) at synapses, 3 inflammatory responses with spinal glial cell activation, 4 the role of endogenous neuropeptides, 5 alterations in opioid receptor function and number 6 and reduced function of inhibitory neurotransmitter receptors 7 among others. Studies have shown that chronic pain occurs in about 5–32% of hysterectomy patients. 8 Inadequate perioperative analgesia and unchecked hyperalgesia engender significant risk for the development of intractable postoperative pain syndromes. 9 Remifentanil possesses unique pharmacokinetic properties, including rapid onset, fleeting half-life, and independence of hepatic and renal clearance, allowing for sustained infusion without bioaccumulation. This pharmacologic profile has enabled the widespread utilization of remifentanil for both acute and chronic analgesia as well as the maintenance of general anesthesia. 10 However, investigations have revealed that among opioid analgesics, remifentanil elicits the highest rates of OIH. 11 In recent years, diverse pharmacological interventions such as ketamine, colistin, non-steroidal anti-inflammatory drugs (NSAIDs), nitric oxide, and magnesium sulfate have demonstrated efficacy in attenuating remifentanil-induced hyperalgesia (RIH) to varying extents in animal models and clinical trials. 12–16 However, supplemental dosing regimens introduce the potential fo -Abstract Truncated-

pharmacology & pharmacy,chemistry, medicinal
Pharmacological interventions for preventing opioid-induced hyperalgesia in adults after opioid-based anesthesia: a systematic review and network meta-analysis

Wei-Ji Xie,Ji-Shuang Hong,Cheng-Fei Feng,Hao-Feng Chen,Wei Li,Yong-Chun Li

DOI: https://doi.org/10.3389/fphar.2023.1199794

IF: 5.6

2023-06-22

Frontiers in Pharmacology

Abstract:Background: Opioid-induced hyperalgesia (OIH) is an adverse event of prolonged opioid use that increases pain intensity. The optimal drug to prevent these adverse effects is still unknown. We aimed to conduct a network meta-analysis to compare different pharmacological interventions for preventing the increase in postoperative pain intensity caused by OIH. Methods: Several databases were searched independently for randomized controlled trials (RCTs) comparing various pharmacological interventions to prevent OIH. The primary outcomes were postoperative pain intensity at rest after 24 h and the incidence of postoperative nausea and vomiting (PONV). Secondary outcomes included pain threshold at 24 h after surgery, total morphine consumption over 24 h, time to first postoperative analgesic requirement, and shivering incidence. Results: In total, 33 RCTs with 1711 patients were identified. In terms of postoperative pain intensity, amantadine, magnesium sulphate, pregabalin, dexmedetomidine, ibuprofen, flurbiprofen plus dexmedetomidine, parecoxib, parecoxib plus dexmedetomidine, and S (+)-ketamine plus methadone were all associated with milder pain intensity than placebo, with amantadine being the most effective (SUCRA values = 96.2). Regarding PONV incidence, intervention with dexmedetomidine or flurbiprofen plus dexmedetomidine resulted in a lower incidence than placebo, with dexmedetomidine showing the best result (SUCRA values = 90.3). Conclusion: Amantadine was identified as the best in controlling postoperative pain intensity and non-inferior to placebo in the incidence of PONV. Dexmedetomidine was the only intervention that outperformed placebo in all indicators. Clinical Trial Registration: https://www.crd.york.ac. uk/prospero/display_record.php?, CRD42021225361.

pharmacology & pharmacy
PREVENTION OF REMIFENTANIL-INDUCED POSTOPERATIVE ACUTE OPIOD TOLERANCE WITH KETAMINE

Yun XUE,Xin-Min WU

DOI: https://doi.org/10.3969/j.issn.1006-9852.2007.06.004

2007-01-01

Abstract:Objective:To observe whether small dose NMDA-receptor antagonist ketamine can prevent remifentanil-induced postoperative acute opiod tolerance. Methods: Fifty-one patients undergoing nephrectomy were randomly allocated to three groups (n=17) and were unpremedicated. Anesthesia was maintained with sevoflurane and nitrous oxide. Patients were assigned to receive no drug infusion (Group C) or remifentanil given by TCI at 4 μg/L (Group R) or remifentanil at 4 μg/L and ketamine 0.5 mg/kg just after the induction, followed by an intraoperative infusion of betamine 0.25 mg/kg until skin closure (Group K). Pain score and morphine consumption were recorded for 48 postoperative hours. Results: The emergence times were significantly shorter in the Group R and K than that in Group C (P<0.01). Pain scores were significantly larger in the Group R than that in Group C during the first 30 postoperative minutes(P<0.05). Pain scores were smaller in the Group K than that in Group R at 30 minutes after operation (P<0.05). Patients in the Group R received more morphine than Group C during the first 24 postoperative hours (P<0.05). During the first 30 postoperative minutes, morphine consumption was less in Group K than Group R (P<0.05). No psychotomimetic symptoms were noted in the three groups. Conclusion: Acute opiod tolerance occurs after remifentanil based inhalation anesthesia. Supplementing with small dose ketamine decreases postoperative pain scores and morphine consumption without increasing the incidence of side effects.
Cytokines, Phagocytes, and Pentoxifylline

G. Mandell

DOI: https://doi.org/10.1097/00005344-199500252-00005

IF: 3.271

Journal of Cardiovascular Pharmacology

Abstract:Phagocytic cells, such as polymorphonuclear neutrophils, monocytes, and macrophages, are essential for defense against infection caused by a variety of microorganisms. The mechanisms used by these cells to destroy microbes comprise a potent oxidative armamentarium including superoxide, hydrogen peroxide, and hypochlorous acid. In addition, granule contents such as proteolytic enzymes, lysozyme, lactoferrin, and myelo-peroxidase are released into the phagosome to destroy ingested microorganisms. Inflammatory cytokines, such as tumor necrosis factor (TNF), interleukin-1 (IL-1), and IL-6, enhance the phagocytic and microbicidal activity of the cells and increase their stickiness. It has been demonstrated in a variety of animal and clinical studies that activated phagocytes can damage the host they are designed to protect, using the mechanisms described above. Alkylxanthines, including pentoxifylline, are potent inhibitors of this inflammatory damage by two major actions: (a) reduction of the production of inflammatory cytokines (especially TNF) by phagocytes stimulated with a variety of microbial products (e.g., endotoxin); and (b) reversal of the effect of these cytokines on phagocytes. Thus, pentoxifylline counteracts the following effects of inflammatory cytokines on phagocytes: increased adherence, shape change resulting in larger size and rigidity, increased oxidative burst, priming for an enhanced oxidative burst, increased degranulation, and decreased chemotactic movement. In addition, these activities synergize with the normal anti-inflammatory mediator adenosine. Alkyxanthines have the potential to be effective therapy for conditions in which inflammatory cytokines and phagocytes cause damage, including the sepsis syndrome, ARDS, AIDS, and arthritis.
Comparison of the recovery profile of sufentanil and remifentanil in total intravenous anesthesia: a systematic review and meta-analysis of randomized controlled trials

Igor Seror Cuiabano,Rafael Pagliaro Naves,Rodrigo Bouchabki de A Diehl

DOI: https://doi.org/10.1016/j.bjane.2024.844558

2024-09-07

Abstract:Introduction: Remifentanil is a short-acting opioid and can be administered during surgery without the risk of delayed postoperative recovery but concerns about hyperalgesia and the shortages of remifentanil lead anesthetists to consider long-acting opioids for Total Intravenous Anesthesia (TIVA). Sufentanil is a more potent opioid with a longer context-sensitive half-life but can promote good postoperative analgesia due to its residual effect. This meta-analysis aimed to compare the recovery profile of remifentanil and sufentanil for TIVA. Methods: The search strategy was performed in PubMed, CENTRAL, and Web of Science for RCTs comparing sufentanil and remifentanil as part of TIVA in adults undergoing noncardiac surgery. Risk of bias and the quality of evidence were performed using RoB2 and GRADEpro, respectively. The primary outcome was time to tracheal extubation. Secondary analyses included postoperative analgesia, respiratory depression, and Postoperative Nausea and Vomiting (PONV). Results: Sufentanil increases the time to extubate, MD = 4.29 min; 95% CI: 2.33 to 6.26; p = 0.001. It also reduces the need for postoperative rescue analgesia, logOR = -1.07; 95% CI: -1.62 to -0.52; p = 0.005. There were no significant differences between both opioids for PONV, logOR = 0.50; 95% CI: -0.10 to 1.10; p = 0.10 and respiratory depression, logOR = 1.21; 95% CI: -0.42 to 2.84; p = 0.15. Conclusion: Sufentanil delays the time to tracheal extubation compared with remifentanil but is associated with a reduced need for postoperative rescue analgesia. No significant differences were observed between the two opioids in terms of postoperative respiratory depression or PONV.
Intraspinal administration of morphine hydrochloride combined with low doses of bupivacaine in hemorrhoidectomy: a clinical randomized trial

Manuel Ruiz-Castro,Marta San José Santos,Antonio Rodríguez-Miguel,Francisco J de Abajo Iglesias

DOI: https://doi.org/10.23736/S0375-9393.17.11762-1

Abstract:Background: Intrathecal local anesthetics, associated or not to opioids, is commonplace in anorectal surgery, but it is unknown which is the option with the best risk-benefit ratio. The main aim was to assess whether the combination of morphine (50 mcg) with low-dose bupivacaine (3 mg) in an intradural solution has a better analgesic short-term effect than bupivacaine alone at standard doses (5 mg) in hemorrhoidectomy. Methods: Sixty-six patients of any sex were randomly assigned to two alternative treatments and 63 patients were considered valid for analysis. Hyperbaric bupivacaine 3 mg combined with 50 mcg of intradural morphine hydrochloride (BUP-MOR group) was compared with 5 mg hyperbaric bupivacaine (BUP group). The primary outcome was pain evaluated through a visual analog scale (from 0 to 100 mm) at 24 hours post-surgery. The proportion of patients requiring rescue analgesia, and those presenting with motor blockade and other adverse events was also compared between the two groups. Results: BUP-MOR group showed a higher efficacy than BUP group in the visual analog scale at 24 hours postsurgery (15±12 vs. 33±22 mm; P<0.001). Also, BUP-MOR group presented a lower percentage of patients who needed rescue analgesia at resuscitation room (6.7% vs. 24.2%; P=0.08) and a lower proportion of patients who had motor blockade (23.3% vs. 51.5%; P=0.02), while they presented a non-significant increased incidence of urinary retention (23.3% vs. 9.0%; P=0.17). Conclusions: The addition of intradural morphine allows a reduction in the dosage of local anesthetic improves short-term postoperative analgesia and is associated with less motor blockade.
Effect of Remimazolam on Pain Perception and Opioid-Induced Hyperalgesia in Patients Undergoing Laparoscopic Urologic Surgery-A Prospective, Randomized, Controlled Study

Cheol Lee,Junsung Lim,Hansol Hong,Hyungjong Yu,Hayoung Lee

DOI: https://doi.org/10.3390/medicina60010123

2024-01-09

Abstract:Background and Objectives: The effects of midazolam, a benzodiazepine, on pain perception are complex on both spinal and supraspinal levels. It is not yet known whether remimazolam clinically attenuates or worsens pain. The present study investigated the effect of intraoperative remimazolam on opioid-induced hyperalgesia (OIH) in patients undergoing general anesthesia. Materials and Methods: The patients were randomized into three groups: group RHR (6 mg/kg/h initial dose followed by 1 mg/kg/h remimazolam and 0.3 μg /kg/min remifentanil), group DHR (desflurane and 0.3 μg /kg/min remifentanil) or group DLR (desflurane and 0.05 µg/kg /min remifentanil). The primary outcome was a mechanical hyperalgesia threshold, while secondary outcomes included an area of hyperalgesia and clinically relevant pain outcomes. Results: Group RHR had a higher mechanical hyperalgesia threshold, a smaller hyperalgesia postoperative area at 24 h, a longer time to first rescue analgesia (p = 0.04), lower cumulative PCA volume containing morphine postoperatively consumed for 24 h (p < 0.01), and lower pain intensity for 12 h than group DHR (p < 0.001). However, there was no significant difference in OIH between groups RHR and DLR. Conclusions: Group RHR, which received remimazolam, attenuated OIH, including mechanically evoked pain and some clinically relevant pain outcomes caused by a high dose of remifentanil. Further research is essential to determine how clinically meaningful and important the small differences observed between the two groups are.
Effects of butorphanol on postoperative hyperalgesia induced by remifentanil anesthesia in patients undergoing laparoscopic cholecystectomy

XU De-jun,ZHANG Li-ping

2013-01-01

Abstract:Objective: To evaluate the effect of butorphanol on postoperative hyperalgesia induced by remifentanil in patients undergoing laparoscopic cholecystectomy.Methods: This prospective study was performed using a randomized,controlled and double-blind design.Sixty ASA I-II patients scheduled for elective laparoscopic cholecystectomy under general anesthesia were randomly divided into 2 groups by drawing lots: control and butorphanol groups.All patients received combined intravenous+inhalational anesthesia,and the anesthesia was maintained with propofol,remifentanil and sevoflurane.Patients in butorphanol group received 20 μg·kg-1 butorphanol after the cholecyst had been removed,and those in control group received the same volume of normal saline.VAS and Ramsay scores were assessed at 30,60 and 120 min after awakeness.Postoperative recovery time of spontaneous breath,the time of awakeness and extubation,the number of patients who need tramadol,and the dosage of tramadol,as well as the adverse reactions such as nausea,vomit and shiver,were recorded for 2 h after surgery.Results: The postoperative VAS scores were higher in control group than in butorphanol group(P<0.05).The number of patents who need tramadol and the tramadol dosage used were lower in butorphanol group than in control group(P<0.05).The adverse reactions(nausea,vomit and shiver) were also lower in butorphanol group than in control group(P<0.05).There was no significant difference between the two groups in Ramsay score and postoperative recovery.Conclusion: Butorphanol has a significant suppressive effect on postoperative hyperalgesia induced by remifentanil-based anesthesia.
Application of Butorphanol versus Sufentanil in Multimode Analgesia via Patient Controlled Intravenous Analgesia After Hepatobiliary Surgery: A Retrospective Cohort Study

Xiaodong Xu,Yuan Tao,Yitian Yang,Jiaqiang Zhang,Mingyang Sun

DOI: https://doi.org/10.2147/dddt.s433136

IF: 4.3188

2023-12-20

Drug Design Development and Therapy

Abstract:Xiaodong Xu, &ast Yuan Tao, &ast Yitian Yang, Jiaqiang Zhang, Mingyang Sun Department of Anesthesiology and Perioperative Medicine, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jiaqiang Zhang; Mingyang Sun, Department of Anesthesiology and Perioperative Medicine, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, People's Republic of China, Tel +0 371 6558 0728, Email ; Purpose: We investigate the efficacy and safety of butorphanol in multimodal analgesia combined with dexmedetomidine and ketorolac via patient-controlled intravenous analgesia (PCIA) after hepatobiliary surgery, as compared with sufentanil. Patients and Methods: Postoperative follow-up data of hepatobiliary surgery patients in Henan Provincial People's Hospital from March 2018 to June 2021 were collected retrospectively and divided into butorphanol group (group B) or sufentanil group (group S) according to the postoperative intravenous controlled analgesia scheme. The baseline characteristics and surgical information of the two groups were matched through propensity score matching (PSM). Results: A total of 3437 patients were screened, and PSM yielded 1816 patients after matching, including 908 in the butorphanol group and 908 in the sufentanil group. Compared with group S, the incidence of moderate-to-severe pain on the first postoperative day and the second postoperative day was lower in group B during rest (3.2% vs 10.9%, P < 0.001; 1.2% vs 4.6%, P < 0.001), and during movement (7.0% vs 18.9%, P < 0.001; 2.6% vs 8.7%, P < 0.001). Patients receiving butorphanol had a lower morphine consumption (50mg vs 120mg, P < 0.001). The bolus attempts of an analgesic pump in group B were significantly lower than in group S (1 vs 2, P < 0.001). Postoperative hospital length of stay was shortened in group B (11d vs 12d, P =0.017). The occurrence of postoperative vomiting was lower in group B (1.4% vs 3.0%, P =0.025) than in group S. However, more patients in group B experienced dizziness (0.9% vs 0.1%, P =0.019). Conclusion: Compared with sufentanil, the application of butorphanol in multimodal analgesia combined with dexmedetomidine and ketorolac via PCIA ameliorated postoperative pain after hepatobiliary surgery, with reduced opioid consumption and shorter postoperative hospital length of stay. Keywords: patient controlled intravenous analgesia, butorphanol, sufentanil, propensity score matching Acute postoperative pain remains one of the most common challenges in patients undergoing hepatobiliary surgery. 1,2 Insufficient analgesia has been associated with increased sympathetic activation, immune suppression, higher risk of cardiovascular and respiratory systems, delayed recovery of gastrointestinal peristalsis function, and adverse psychological emotions. 3,4 If not well controlled in the initial stage, acute pain may result in peripheral and central sensitization, and evolve into chronic pain after surgery. 5–7 Therefore, adequate postoperative analgesia is fundamental and acts as a core principle in the context of the Enhanced Recovery After Surgery (ERAS) program. 8,9 Considering that pain patterns in patients receiving hepatobiliary surgery are multifactorial and differ from other procedures, effective multimodal analgesia with the combination of differing targeting pain pathways has been suggested to be the optimal pain management in abdominal surgery. 10,11 Current evidence emphasizes the growing interest in novel techniques, including intrathecal morphine, truncal nerve blocks, as well as emerging analgesics including esketamine, 5-HT 3 -antagonists, and so on. 2,12–16 However, opioids are still utilized as the first-line choice for perioperative pain management due to their powerful rapid-onset systematic analgesic effect. 17 Meanwhile, they could also induce a high incidence of opioid-related side effects, including delayed respiratory depression, nausea and vomiting, urinary retention, itching, dizziness, and so on. 4 Strategies to minimize opioid consumption, whilst optimizing patient comfort and postoperative recovery are of priority. Butorphanol, an opioid receptor agonist-antagonist, has been widely used in postoperative pain management recently. Butorphanol mainly acts on the κ receptors in the presynaptic and postsynaptic membranes of neurons in the central nervous system. By inhibiting adenylyl cyclase, it reduces the intracellular cyclic adenosi -Abstract Truncated-

pharmacology & pharmacy,chemistry, medicinal
Securely Computing Three-Input Functions with Eight Cards

Takuya Nishida,Yu-ichi Hayashi,T. Mizuki,H. Sone

DOI: https://doi.org/10.1587/TRANSFUN.E98.A.1145

2015-06-01

IEICE Transactions on Fundamentals of Electronics Communications and Computer Sciences

Abstract:
Distributed virtual environments for military training applications: Trends and challenges

Surachai Chieochan,P. Pratoomma,C. Kumsap

DOI: https://doi.org/10.1109/ACDT.2015.7111578

2015-04-23

Abstract:An introductory tutorial of distributed virtual environments for military training applications is provided. Current trends and research focus in the distributed virtual environment arena are discussed from both the modeling and simulation points of view.
Preemptive Analgesia with a Single Low Dose of Intrathecal Morphine in Multilevel Posterior Lumbar Interbody Fusion Surgery: a Double-Blind, Randomized, Controlled Trial

Yujie Wang,Xiangyang Guo,Zhaoqing Guo,Mao Xu

DOI: https://doi.org/10.1016/j.spinee.2020.03.001

2020-01-01

Abstract:BACKGROUND CONTEXT: Patients undergoing lumbar spinal surgery may experience consid- erable pain in the early postoperative period, and poor pain control after multilevel lumbar spinal fusion surgery is frequently associated with multiple complications and delayed discharge from hospital. PURPOSE: The current study evaluated the efficacy and safety of preemptive analgesia with intra- thecal morphine (ITM) in patients undergoing multilevel posterior lumbar spinal fusion surgery. STUDY DESIGN: Double -blinded, randomized, controlled trial. PATIENT SAMPLE: Ninety-two patients aged between 18 and 80 years who were scheduled to undergo elective lumbar laminectomy (L3 -S1) and dual -level fusions. OUTCOME MEASURES: The primary endpoint was the degree of postoperative pain at rest and during movement evaluated using a 10 -point visual analogue scale. The secondary outcomes included the consumption of analgesics, the patient -assessed postoperative and satisfaction scores, adverse effects, time to first ambulation, and length of hospital stay. METHODS: Patients were randomly allocated to either the ITM group that received 0.2 mg of ITM or the control (CON) group that received 2 ml of 0.9% saline as a skin infiltration 30 minutes prior to anesthesia induction. RESULTS: The ITM group had a significantly lower visual analogue scale score than the CON group during the first 3 days postoperatively (at rest, P=0.000, during movement, P=0.000). The ITM group used significantly less sufentanil than the CON group in the first 3 days postoperatively (p=.000) in patient -controlled intravenous analgesia, as well as in supplemental analgesic demands. The ITM group reported a greater degree of satisfaction with the whole hospitalization experience than the CON group (2.4 +/- 0.6 vs. 1.9 +/- 0.6, p=.000). The two groups did not significantly differ regarding adverse effects, length of hospital stay, and time taken to regain the ability to walk with- out support. CONCLUSIONS: Preemptive analgesia with ITM results in significantly improved early postop- erative pain control and decreased postoperative patient -controlled intravenous analgesia consump- tion, with no increase in adverse effects. (c) 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY -NC -ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
The efficacy of dexmedetomidine administration of remifentanil given on postoperative pain and hyperalgesia

zhang miaoqing,chen xinzhong

2014-01-01

Abstract:Objective To study dexmedetomidine administration of remifentanil given post operative pain and hyperalgesia induced effects. Methods Total intravenous anesthesia randomly selected lower abdominal laparotomy and laparoscopic surgery of the 80 cases, press the right medetomidine dose were divided into small doses(0.2μg/kg)dexmedetomidine given group(LDex group), medium dose(0.6μg/kg) dexmedetomidine given group(MDex group) and high dose(1μg/kg) dexmedetomidine given group(HDex group) and control group,each of 20 cases, compared the group remifentanil fentanyl dosage, tramadol dosage, mechanically pain threshold, VAS pain and Ramsay score. Results The patient group HDex open surgery without the use of postoperative analgesic tramadol, laparoscopic surgery group MDex group and HDex group were without the use of tramadol. Open surgery and laparoscopic surgery group group mechanical pain threshold were associated with the amount of dexmedetomidine had negative correlation(r = 0.42, 0.43,P <0.05), laparotomy high dose(1μg/kg) dexmedetomidine 24h after extubation care given microphone returned to normal, laparoscopy dose(0.6μg/kg) dexmedetomidine given 24h after extubation basically returned to normal. Open surgery and laparoscopic surgery group pain scores were associated with the amount of dexmedetomidine had negative correlation(r =-0.39,-0.41, P <0.05). Conclusion Dexmedetomidine set at laparotomy or laparoscopic surgery can reduce pre-administration of remifentanil induced postoperative pain sensation and hyperalgesia in a dose-dependent effect, the dose required in open surgery is higher than in laparoscopic surgery.
ICU patients receiving remifentanil do not experience reduced duration of mechanical ventilation: a systematic review of randomized controlled trials and network meta-analyses based on Bayesian theories

Fangjie Lu,Sirun Qin,Chang Liu,Xunxun Chen,Zhaoqiu Dai,Cong Li

DOI: https://doi.org/10.3389/fmed.2024.1370481

IF: 3.9

2024-08-07

Frontiers in Medicine

Abstract:Background The purpose of this network meta-analysis (NMA) was to evaluate the efficacy of intravenous opioid μ-receptor analgesics in shortening the duration of mechanical ventilation (MV) in ICU patients. Methods Randomized controlled trials comparing the efficacy of remifentanil, sufentanil, morphine, and fentanyl on the duration of MV in ICU patients were searched in Embase, Cochrane, Pubmed, and Web of Science electronic databases. The primary outcome was MV duration. The Bayesian random-effects framework was used to evaluate relative efficacy. Results In total 20 studies were included in this NMA involving 3,442 patients. Remifentanil was not associated with a reduction in the duration of MV compared with fentanyl (mean difference (MD) -0.16; 95% credible interval (CrI): −4.75 ~ 5.63) and morphine (MD 3.84; 95% CrI: −0.29 ~ 10.68). The secondary outcomes showed that, compared with remifentanil, sufentanil can prolong the duration of extubation. No regimen significantly shortened the ICU length of stay and improved the ICU mortality, efficacy, safety, and drug-related adverse events. Conclusion Among these analgesics, remifentanil did not appear to be associated with a reduction in MV duration. Clinicians should carefully titrate the analgesia of MV patients to prevent a potentially prolonged duration of MV due to excessive or inadequate analgesic therapy. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , CRD42021232604.

medicine, general & internal
Application of sufentanil to prevent acute postoperative pain in laparoscopic cholecystectomy with remifentanil-based anesthesia

Qun FU,Yongquan CHEN,Xiaoju JIN

DOI: https://doi.org/10.3969/j.issn.1003-3548.2011.04.007

IF: 5.41

2011-01-01

Clinical Medicine

Abstract:Objective To observe the efficiency and safety of sufentanil which used in laparoscopic cholecystectomy with remifentanil-based anesthesia to prevent the acute postoperative pain.Methods Forty patients were randomly and blindly assigned to sufentanil group(group S) and non-sufentanil group(group C,20 cases in each group).Suspended isoflurane and vecuronium 30 minutes before the end of surgery then stoped using propofol remifentanil at the end of surgery,while the former group was injected sufentanil with 0.1 μg/kg.VAS,SpO2,HR,SBP,DBP were observed at post-operative 1 h(T1),2 h(T2),4 h(T3),6 h(T4),12 h(T5),24 h(T6),recorded the complications of nausea,vomiting,irritability and so on.Results VAS of group S was significantly lower than that of group C at T1,T2,T3,T5(P<0.01),the VAS score was lower than that of group C at T4,T6(P<0.05),there was no significant difference between group S and group C in SpO2,HR,SBP,DPB at T1,T2,T3,T4,T5,T6(P>0.05),and there was no significant difference in nausea,vomiting,irritability in the two groups(P>0.05).Conclusion At the end of surgery,injected 0.1 μg/kg sufentanil to control the acute postoperative pain of remifentanil and hyperalgesia effectively,analgesia without affecting the awakening quality,no respiratory depression occurred,which is secure,flexible and effective analgesia after the laparoscopic cholecystectomy.
Preemptive Intravenous Nalbuphine for the Treatment of Post-Operative Visceral Pain: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Xiaofen Liu,Jun Hu,Xianwen Hu,Rui Li,Yun Li,Gordon Wong,Ye Zhang,Lili Tang,Xiaoqing Chai,Yanhu Xie,Meijing Lu,Xiaoqiong Xia,Jiyuan Wang,Xiang Gao,Qing Zhang,Xin Wang,Qi Zhang,Shengbin Wang,Xia Ju,Jinbao Chen,Fang Gao,Xiuting Men,Chunhong Liu,Xiaoyun Yang,Hui Xu,Xiaoxia Wang,Rui Zhan,Ling Wang,Hui Wang,

DOI: https://doi.org/10.1007/s40122-021-00275-8

IF: 3.96

2021-06-04

Pain and Therapy

Abstract:IntroductionPost-operative visceral pain is common in early postoperative period after laparoscopic surgery. As a kappa opioid receptor agonist, the antinociceptive effects of nalbuphine in visceral pain are consistent across a multitude of experimental conditions irrespective of species. We hypothesized that preemptive nalbuphine can decrease the visceral pain for patients with incisional infiltration of ropivacaine after laparoscopic cholecystectomy.MethodsIn a multicenter, prospective, double-blind, placebo-controlled, randomized clinical trial, 2094 participants scheduled for laparoscopic cholecystectomy were randomly assigned to receive nalbuphine (Nal group, n = 1029) or placebo (Con group, n = 1027). The Nal group received intravenous nalbuphine 0.2 mg·kg−1 and the Con group received saline in a similar way. The primary endpoint was the effect of nalbuphine on post-operative visceral pain intensity scores within 24 h postoperatively. The total amount of analgesic as well as complications were recorded.ResultsA total of 1934 participants were analyzed. Nalbuphine reduced the visceral pain both at rest (β = − 0.1189, 95% CI − 0.23 to − 0.01, P = 0.037) and movement (β = − 0.1076, 95% CI − 0.21 to − 0.01, P = 0.040) compared with placebo. Patients in the Nal group required less frequent supplemental analgesic administration during the first 24 h after surgery. There were fewer patients in the Nal group who experienced nausea and vomiting (PONV) (P = 0.008).ConclusionsPreemptive nalbuphine administered at a dose of 0.2 mg·kg−1 was safe and effective at reducing the postoperative visceral pain and supplemental analgesic use in patients undergoing laparoscopic cholecystectomy.Trial RegistrationChinese Clinical Trial Registry; ChiCTR1800014379.

clinical neurology
Intraoperative Electroacupuncture Relieves Remifentanil-Induced Postoperative Hyperalgesia Via Inhibiting Spinal Glial Activation in Rats

Changxi Shi,Yue Liu,Wei Zhang,Yishan Lei,Cui'e Lu,Rao Sun,Yu'e Sun,Ming Jiang,Xiaoping Gu,Zhengliang Ma

DOI: https://doi.org/10.1177/1744806917725636

IF: 3.37

2017-01-01

Molecular Pain

Abstract:Background Accumulating studies have suggested that remifentanil, the widely-used opioid analgesic in clinical anesthesia, can activate the pronociceptive systems and enhance postoperative pain. Glial cells are thought to be implicated in remifentanil-induced hyperalgesia. Electroacupuncture is a complementary therapy to relieve various pain conditions with few side effects, and glial cells may be involved in its antinociceptive effect. In this study, we investigated whether intraoperative electroacupuncture could relieve remifentanil-induced postoperative hyperalgesia by inhibiting the activation of spinal glial cells, the production of spinal proinflammatory cytokines, and the activation of spinal mitogen-activated protein kinases. Methods A rat model of remifentanil-induced postoperative hyperalgesia was used in this study. Electroacupuncture during surgery was conducted at bilateral Zusanli (ST36) acupoints. Behavior tests, including mechanical allodynia and thermal hyperalgesia, were performed at different time points. Astrocytic marker glial fibrillary acidic protein, microglial marker Iba1, proinflammatory cytokines, and phosphorylated mitogen-activated protein kinases in the spinal cord were detected by Western blot and/or immunofluorescence. Results Mechanical allodynia and thermal hyperalgesia were induced by both surgical incision and remifentanil infusion, and remifentanil infusion significantly exaggerated and prolonged incision-induced pronociceptive effects. Glial fibrillary acidic protein, Iba1, proinflammatory cytokines (interleukin-1β and tumor necrosis factor-α), and phosphorylated mitogen-activated protein kinases (p-p38, p-JNK, and p-ERK1/2) were upregulated after surgical incision, remifentanil infusion, and especially after their combination. Intraoperative electroacupuncture significantly attenuated incision- and/or remifentanil-induced pronociceptive effects, spinal glial activation, proinflammatory cytokine upregulation, and phosphorylated mitogen-activated protein kinase upregulation. Conclusions Our study suggests that remifentanil-induced postoperative hyperalgesia can be relieved by intraoperative electroacupuncture via inhibiting the activation of spinal glial cells, the upregulation of spinal proinflammatory cytokines, and the activation of spinal mitogen-activated protein kinases.
Intravenous Methadone versus Intrathecal Morphine as Part of an Enhanced Recovery After Cardiac Surgery Protocol on Postoperative Pain and Outcomes: A Retrospective Cohort Study

Luca LaColla,Maria A Nanez,Stephen Frabitore,Danielle R Lavage,Nav Warraich,Charles Luke,Ibrahim Sultan,Senthilkumar Sadhasivam,Kathirvel Subramaniam

DOI: https://doi.org/10.1053/j.jvca.2024.06.032

Abstract:Objectives: Evaluate the effect of intravenous (IV) methadone versus intrathecal morphine (ITM) within an Enhanced Recovery After Cardiac Surgery (ERACS) pathway on postoperative pain and outcomes (length of hospital stay and postoperative complications) after cardiac surgery. Design: Retrospective cohort study. Setting: Two tertiary academic medical institutions within the same health system. Participants: Eligible 289 adult patients undergoing elective cardiac surgery with an enhanced recovery pathway from January 2020 through July 2021. Interventions: Patients were administered ITM (0.25 mg) or IV methadone (0.1 mg/kg) if ITM was contraindicated. All patients were enrolled in an ERACS pathway using current Enhanced Recovery After Surgery society guidelines. Measurements and main results: Primary outcome measures included postoperative pain scores and opioid consumption measured as oral morphine equivalents. We analyzed patient demographics, procedural factors, intraoperative medications, and outcomes. Adjusted linear mixed models were fit to analyze associations between intervention and pain outcomes. ITM was associated with decrease in pain scores on postoperative day 0 after adjusting for clinical variables (average marginal effect, 0.49; 95% confidence interval, 0.002-0.977; p = 0.049). No difference in opioid consumption could be demonstrated between groups after adjusting for postoperative day and other variables of interest. Conclusions: ITM when compared with IV methadone was associated with a decrease in pain scores without any difference in opioid consumption after elective cardiac surgery. Methadone can be considered as a safe and effective alternative to ITM for ERACS protocols. Future large prospective studies are needed to validate this finding and further improve analgesia and safety.
Immune function after major surgical interventions: the effect of postoperative pain treatment

Giada Amodeo,Dario Bugada,Silvia Franchi,Giorgia Moschetti,Stefania Grimaldi,Alberto Panerai,Massimo Allegri,Paola Sacerdote

DOI: https://doi.org/10.2147/JPR.S158230

2018-07-10

Abstract:Introduction: Impaired immune function during the perioperative period may be associated with worse short- and long-term outcomes. Morphine is considered a major contributor to immune modulation. Patients and methods: We performed a pilot study to investigate postoperative immune function by analyzing peripheral blood mononuclear cells' functionality and cytokine production in 16 patients undergoing major abdominal surgery. All patients were treated with intravenous (i.v.) patient-controlled analgesia with morphine and continuous wound infusion with ropivacaine+methylprednisolone for 24 hours. After 24 hours, patients were randomized into two groups, one continuing intrawound infusion and the other receiving only i.v. analgesia. We evaluated lymphoproliferation and cytokine production by peripheral blood mononuclear cells at the end of surgery and at 24 and 48 hours postoperatively. Results: A significant reduction in TNF-α, IL-2, IFN-γ and lymphoproliferation was observed immediately after surgery, indicating impaired cell-mediated immunity. TNF-α and IFN-γ remained suppressed up to 48 hours after surgery, while a trend to normalization was observed for IL-2 and lymphoproliferation, irrespective of the treatment group. A significant inverse correlation was present between age and morphine and between age and lymphoproliferation. No negative correlation was present between morphine and cytokine production. We did not find any differences within the two groups between 24 and 48 hours in terms of morphine consumption and immune responses. Conclusion: A relevant depression of cell-mediated immunity is associated with major surgery and persists despite optimal analgesia. Even though morphine may participate in immunosuppression, we did not retrieve any dose-related effect.

Assessment of “Ca2+-antagonist” effects of drugs in K+-depolarized smooth muscle

Buprenorphine for Chronic Pain Treatment and Elective Orthopaedic Surgery: a US National Database Analysis

Effects of Remifentanil Gradual Withdrawal Combined with Postoperative Infusion on Postoperative Hyperalgesia in Patients Undergoing Laparoscopic hysterectomy: A Factorial Design, Double-Blind, Randomized Controlled Trial

Pharmacological interventions for preventing opioid-induced hyperalgesia in adults after opioid-based anesthesia: a systematic review and network meta-analysis

PREVENTION OF REMIFENTANIL-INDUCED POSTOPERATIVE ACUTE OPIOD TOLERANCE WITH KETAMINE

Cytokines, Phagocytes, and Pentoxifylline

Comparison of the recovery profile of sufentanil and remifentanil in total intravenous anesthesia: a systematic review and meta-analysis of randomized controlled trials

Intraspinal administration of morphine hydrochloride combined with low doses of bupivacaine in hemorrhoidectomy: a clinical randomized trial

Effect of Remimazolam on Pain Perception and Opioid-Induced Hyperalgesia in Patients Undergoing Laparoscopic Urologic Surgery-A Prospective, Randomized, Controlled Study

Effects of butorphanol on postoperative hyperalgesia induced by remifentanil anesthesia in patients undergoing laparoscopic cholecystectomy

Application of Butorphanol versus Sufentanil in Multimode Analgesia via Patient Controlled Intravenous Analgesia After Hepatobiliary Surgery: A Retrospective Cohort Study

Securely Computing Three-Input Functions with Eight Cards

Distributed virtual environments for military training applications: Trends and challenges

Preemptive Analgesia with a Single Low Dose of Intrathecal Morphine in Multilevel Posterior Lumbar Interbody Fusion Surgery: a Double-Blind, Randomized, Controlled Trial

The efficacy of dexmedetomidine administration of remifentanil given on postoperative pain and hyperalgesia

ICU patients receiving remifentanil do not experience reduced duration of mechanical ventilation: a systematic review of randomized controlled trials and network meta-analyses based on Bayesian theories

Application of sufentanil to prevent acute postoperative pain in laparoscopic cholecystectomy with remifentanil-based anesthesia

Preemptive Intravenous Nalbuphine for the Treatment of Post-Operative Visceral Pain: A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Intraoperative Electroacupuncture Relieves Remifentanil-Induced Postoperative Hyperalgesia Via Inhibiting Spinal Glial Activation in Rats

Intravenous Methadone versus Intrathecal Morphine as Part of an Enhanced Recovery After Cardiac Surgery Protocol on Postoperative Pain and Outcomes: A Retrospective Cohort Study

Immune function after major surgical interventions: the effect of postoperative pain treatment